Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Major vascular anomalies found in brains of people with Huntington's disease

  • Cancer and chemobrain: Cancer diagnosis affects cognitive function

  • Epilepsy drug may preserve eyesight for people with multiple sclerosis

  • Should they stay or should they go? Study finds no harm from hospital policies that let families observe CPR

  • Difficult to break the soda habit? Sugar-sweetened beverages suppress body's stress response

  • Electronic micropump to deliver treatments deep within the brain

  • Increasing evidence points to inflammation as source of nervous system manifestations of Lyme disease

  • Scientists use brain stimulation to boost creativity, set stage to potentially treat depression

  • Botox makes unnerving journey into our nervous system

  • A sniff of happiness: Chemicals in sweat may convey positive emotion

  •